Is Deregulation the Only Answer to Getting More Affordable Drugs to Market Faster?

By Joe Goodman, July, 2017

Earlier this year, in his first address to Congress, President Trump criticized the FDA’s drug approval process saying the length of time in which drugs need to be approved is “slow and burdensome.” Joe Goodman, Director of Solutions Consulting at Sparta Systems, weighs the potential outcomes of deregulation to examine whether it is the only means by which to quickly introduce new and affordable medications.

To read the complete article click here

© 1995-2017 Sparta Systems, Inc. All Rights Reserved.
© 1995-2017 Sparta Systems, Inc. All Rights Reserved.Sparta Systems Logo